The domestically-made cervical cancer vaccine is only half the price of imported ,
it only costs about 1,000 yuan for an adult to vaccinate the whole course.
The domestic bivalent vaccine for cervical cancer started its first injection in Beijing last week.
This lady can complete the vaccination procedure after receiving the first vaccination one month and six months after receiving the vaccination again, which can effectively avoid the 84.5% risk of cervical cancer.
This means that my country has got rid of the situation where cervical cancer vaccines are totally dependent on imports.
Currently, there are two types of bivalent cervical cancer vaccines on the market in my country: imported and domestically produced. Which one is more suitable for the public?
It is understood that the price of this domestic cervical cancer vaccine is 329 yuan per shot, plus the injection fee, the cost of the three shots is only about 1,000 yuan, which is half the price of the imported bivalent vaccine.
In addition to the price advantage, for the low-age group, the domestic bivalent vaccine has another advantage that the course of vaccination is short.
Advantage 1: The price is half cheaper
It is understood that the price of imported HPV vaccines is generally high. For example, the full cost of the nine-valent vaccine is about 4,000 yuan, and the imported bivalent vaccine is about 2,000 yuan.
The price of a domestic bivalent vaccine is 329 yuan, plus the injection fee of 25 yuan. Adults only need to spend about 1,000 yuan for the entire injection, which is half the price of imported bivalent vaccine.
The price of vaccination for the 9 to 14-year-old age group who only needs two injections will be cheaper.
Advantage two: shorten the course of vaccination
The manufacturer of this domestic HPV vaccine is Xiamen Wantai Canghai Biotechnology Co., Ltd., and its trade name is "Xinkening".
The instructions show that the 9 to 14-year-old vaccinators only need to vaccinate twice to complete the entire course of treatment.
This is the first time that the two-injection method of cervical cancer vaccine has been approved in China.
At present, imported HPV vaccines are not approved for two-injection in China.
The description of imported vaccines for the 9 to 14-year-old young age group can be vaccinated with two doses, and there is no data for Chinese people.
After a 7-month follow-up of 975 volunteers in the bridging clinical trial of Wantai HPV vaccine, it was found that the effects of two doses within half a year of 9 to 14-year-old vaccinators were the same as those of three doses for older age vaccinators.
Advantage three: young people can be vaccinated
At present, the applicable age of the bivalent HPV vaccine on the domestic market is 9 to 45 years old; the applicable population of the nine-valent HPV vaccine is 16-26 years old women; the applicable age of the quadrivalent HPV vaccine is 20 to 45 years old.
The Director-General of the World Health Organization put forward the strategic goal of global elimination of cervical cancer at the World Health Assembly in 2018. By 2030, 90% of 9-14-year-old girls worldwide need to be vaccinated against HPV.
On December 31, 2019, the National Medical Products Administration issued an announcement stating that the approved Xiamen Wantai Canghai Biotechnology Co., Ltd. bivalent human papillomavirus vaccine (E. coli) (trade name: Cecolin) was listed for registration Application.
It is understood that the vaccine is my country’s first cervical cancer vaccine independently developed by Wantai Company and Xiamen University and transformed by Wantai. This is the first cervical cancer vaccine approved in China, which means that China’s cervical cancer vaccine Will end the history of relying on imports.
Prior to this, only the bivalent vaccine of GlaxoSmithKline and Merck's quadrivalent and 9-valent vaccines were on the market in the world.
prompt
Both bivalent and quadrivalent vaccines can defend
The two most dangerous precancerous lesions
Cervical cancer vaccine, also known as HPV vaccine, is a vaccine to prevent the onset of cervical cancer.
Cervical cancer is mainly caused by infection with human papillomavirus (HPV). This vaccine effectively prevents the occurrence of related cervical precancerous lesions and cervical cancer by preventing the infection of HPV subtypes covered by the vaccine.
Studies have found that 99.7% of cervical cancers are caused by HPV infection. HPV can also cause other relatively rare cancers, such as laryngeal cancer, lung cancer and anal cancer.
It is understood that there are currently more than 100 known types of HPV viruses, of which at least 14 genotypes (called "high-risk types") are considered to cause cervical cancer.
The bivalent HPV vaccine has a protective effect on two high-risk types (HPV-16 and HPV-18).
At present, domestic cervical cancer vaccines include imported bivalent, quadrivalent, and quaternary vaccines and domestic bivalent vaccines.
Studies have shown that more than 84.5% of cervical cancers are infected by HPV (papillomavirus) 16 and HPV18 viruses. The domestically marketed bivalent and quadrivalent vaccines can protect against these two most dangerous precancerous lesions and pose a risk to cervical cancer. The prevention and control rate can reach 84.5%.
The nine-valent vaccine has a 90% prevention and control rate of cervical cancer risk.
The public can choose to vaccinate different types of vaccines according to their own age and economic status.
As early as 2017, the World Health Organization also clearly pointed out that existing evidence shows that from a public health perspective, bivalent, quadrivalent and ninth-valent vaccines have no immunogenicity, efficacy and effectiveness in preventing HPV-related types 16 and 18 of cervical cancer. Differences, all three vaccines can prevent most related cancers.
Medical experts said that there is no need to worry about the price, the important thing is to vaccinate as soon as possible to benefit as soon as possible.
It should be noted that yesterday afternoon, a reporter from the Beijing Youth Daily called a community health center in Beijing to inquire about domestic cervical cancer vaccine injections. The medical staff who answered the phone said that at present, in order to ensure that the population has been vaccinated for the second and first injections. For the three-dose vaccination, the first vaccination cannot be provided temporarily, but you can leave a phone number so that the community health center can contact the person who made the appointment when the vaccine is more sufficient.
Text/Reporter Zhao Xinpei Coordinator/Yu Meiying